The myocardial band, a remarkable feature in cardiac anatomy, goes by various names, including myocardial bridging. This structure, formed by interwoven muscle fibers, manifests as a bridge-like formation over a segment of the coronary artery. Despite being recognized as a typical anatomical variation, the presence of a myocardial bridge prompts unique considerations in the realm of physiology. Researchers have dedicated efforts to unravel the intricacies surrounding the myocardial band, investigating its potential implications on coronary blood flow and its associations with specific cardiac conditions. The comprehensive comprehension of this cardiac element holds substantial importance in the field of cardiology, offering healthcare professionals profound insights into its influence on heart function and potential implications for cardiovascular health.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States